Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monosialotetrahexosylganglioside + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Fidia Farmaceutici
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Monosialotetrahexosylganglioside (GM1) + paclitaxel is a combination therapy being investigated for the prevention or treatment of chemotherapy-induced peripheral neuropathy (CIPN). GM1 is a neuroprotective glycosphingolipid that repairs nerves and has antioxidant properties, while paclitaxel is a chemotherapeutic agent commonly used in breast cancer treatment that is known to cause peripheral neurotoxicity. The combination is being studied to determine if GM1 can reduce or prevent the neuropathy caused by paclitaxel treatment.
02
Targets
GEM (Neuronal plasma membrane ganglioside-rich microdomain)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on monosialotetrahexosylganglioside + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monosialotetrahexosylganglioside + paclitaxel.